^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Glioma |
| Regimen: | (lomustine + Matulane (procarbazine hydrochloride) + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.
Excerpt:
Both the IDHmut/non-co-deleted and IDHmut/co-deleted subgroups were significantly correlated with longer PFS (HR = 0.32; p = 0.003; HR = 0.13; p < 0.001) and OS (HR = 0.38; p = 0.013; HR = 0.21; p = 0.029) in the RT plus PCV arm, respectively.
DOI:
10.1200/JCO.2019.37
Trial ID:
